The Kidney Transplant Market, estimated at USD 9.96 Bn in 2025, is expected to exhibit a CAGR of 4.6% and reach USD 13.65 Bn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
Market Dynamics:
Increasing prevalence of chronic kidney diseases is a major driver augmenting the growth of the global kidney transplant market. According to the National Kidney Foundation, in the U.S., approximately 37 million adults are estimated to have chronic kidney disease. Chronic kidney disease is a major risk factor for kidney failure. Besides this, technological advancements in transplant procedures are also expected to fuel the market growth during the forecast period. Developments, such as robotic transplants, use of antirejection drugs, and improved diagnostic techniques, have increased the success and survival rates of transplant patients. Advancements ensure minimal invasiveness, quicker recovery, and greater precision. This has boosted patient's confidence in opting for transplant procedures.
Increasing Prevalence of Kidney Diseases is Driving the Market Growth
The rising prevalence of chronic kidney diseases and kidney failure globally is a major factor augmenting the growth of the kidney transplant market. According to the U.S. National Kidney Foundation, over 37 million American adults suffer from chronic kidney disease. The high occurrence of diabetes, hypertension, and obesity—which are among the leading causes of kidney diseases—is further contributing to the increasing patient pool requiring kidney transplants. Besides, growing geriatric population also plays a significant role as older individuals are more susceptible to chronic conditions damaging the kidneys. These issues are boosting the demand for kidney transplantation procedures worldwide.
Advancements in Immunosuppressive Drugs are Expanding Market Reach
Technological advancements in immunosuppressive medications allowing successful transplantation with improved outcomes are encouraging more patients to opt for kidney transplantation. For instance, the availability of new generation drugs such as belatacept (Nulojix) and basiliximab (Simulect) that provide better organ acceptance are boosting the market growth. Moreover, improvements in drugs delivery methods and formulations augmenting efficacy and safety profiles are widening the eligible donor pool. This, in turn, is enabling more patients suffering from complex conditions to undergo transplantation with a reduced risk of organ rejection. Such medical innovations are positively influencing the adoption of kidney transplantation therapy.
High Cost of Treatment Acts as Significant Market Deterrent
The substantial expense associated with kidney transplantation including the costs of drugs, surgery, hospital stay, medical tests, and post-care poses a major restraint on the market expansion. The high financial burden poses affordability issues for a large patient population around the world, compelling them to delay or avoid transplantation altogether. For instance, the total cost of a kidney transplant in the U.S. ranges from US$230,000 to $400,000 on average, while the annual drug expenses are estimated to be over US$25,000. This hefty price tag remains a key roadblock to universal access and widespread adoption of kidney transplantation therapy.
Shortage of Organ Donors Hampers Market Growth
The acute shortage of viable kidney donors is another key factor limiting the growth prospects of the kidney transplantation market. With a huge gap between the demand and supply of donor organs, a vast number of patients awaiting transplantation are unable to receive transplants on time or may perish before receiving one due to lack of suitable donors. For example, according to the US Health Resources and Services Administration data, over 90,000 Americans are on the waitlist for kidney transplantation against a supply of around 17,000 kidneys from deceased donors annually. The severe donor crunch delays transplantation and necessitates longer dialysis treatments for most patients.
Advancing Technologies on Organ Bioprinting Present Lucrative Opportunities
Emerging bioprinting technologies allowing 3D printing of transplantable living organs offer immense opportunities to overcome the challenges of organ shortage in the future. Significant investments are being made by industry players and researchers to develop processes for printing customized kidney tissues and whole organs using the patient's own cells. For instance, a biotechnology company, Modern Meadow, is working on 3D printing vascularized thick tissues for partial organ reconstruction. Such advancements presenting the possibility of limitless organs custom-made for individual patients could revolutionize transplantation practices and open new avenues for tremendous market growth over the long run.
Increasing Focus on Living Donor Transplants is an Emerging Trend
With deceased donor organs unable to meet the vast recipient needs, more patients and care centers are embracing living donor transplantation as a feasible alternative. Initiatives toward promoting public awareness, streamlining the donor evaluation process, and minimizing financial barriers are encouraging more individuals to volunteer as living donors. In addition, advancements enabling reduced recovery times along with minimally-invasive donor surgery techniques are making living donation safer and more preferred. Stakeholders are capitalizing on this trend by introducing targeted educational programs, reimbursement schemes, and infrastructure support to boost living donor rates and address the organ shortage issue spurring untapped market potential.
Link - https://www.coherentmarketinsights.com/market-insight/kidney-transplant-market-4887
Key Development
- On May 8, 2024, the U.S. Department of Health and Human Services (HHS), via the Centers for Medicare & Medicaid Services (CMS), launched the Increasing Organ Transplant Access (IOTA) Model to improve kidney transplant access, quality of care, and reduce disparities. The model targets transplant hospitals, requiring a minimum of 11 transplants annually over three years. Participating hospitals must develop health equity plans. The proposed rule can be found in the Federal Register, with standard provisions applicable to model participants starting January 1, 2025.
- On April 24, 2024, the National Kidney Registry (NKR) celebrated its 9,000th successful living kidney donor transplant at Hartford Hospital, making it the world's largest kidney paired donation registry. NKR now oversees 25% of all living donor transplants in the U.S., up from 23% in 2023. It facilitates over 1,000 transplants annually, aided by initiatives like microsites, Donor Connect, and Donor Shield, ensuring support and protection for donors.
- In February 2022, Bio-Techne Corporation, a global developer, manufacturer, and supplier of high-quality reagents, analytical instruments, partnered with Thermo Fisher Scientific, a global pharmaceutical and biotechnology company, to exclusively develop and commercialize the ExoTRU kidney transplant rejection test from Exosome Diagnostics, a Bio-Techne Corporation brand. ExoTRU is a non-invasive urine-based liquid biopsy assay that provides essential allograft health information to aid clinicians in managing kidney transplant patients and optimizing care. The assay has the potential to distinguish between T-cell mediated rejection (TCMR) and antibody mediated rejection (ABMR), crucial for improving patient outcomes.
- In April 2021, Sanofi, a global healthcare and pharmaceutical company, agreed to merge with Kadmon Holdings, Inc, a biopharmaceutical company, acquiring Rezurock (belumosudil), a first-in-class treatment for chronic graft-versus-host disease (cGVHD). This aligns with Sanofi's strategy to expand its general medicines core assets.
Key Players: Sanofi, Sangamo Therapeutics, Inc., Pfizer, Inc., Novartis AG, B. Braun Melsungen AG, Fresenius Medical Care, Medtronic, Preservation Solution Inc., TransMedics, Inc., Organ Recovery Systems, Transonic Systems Inc., CareDx, DaVita Kidney Care, ZONAL TRANSPLANT CO-ORDINATION CENTRE, Histogen, F. Hoffmann-La Roche Ltd., Astellas Pharma, Inc., Bristol-Myers Squibb Company, OrganOx Limited, and Terumo Corporation
Contact Us